Dalteparin
-
Subject Areas on Research
- A multi-dose pharmacokinetic study of dalteparin in haemodialysis patients.
- A retrospective analysis of outcomes of dalteparin use in pediatric patients: a single institution experience.
- Activation of the inflammation, coagulation, and fibrinolysis systems, without influence of abciximab infusion in patients with non-ST-elevation acute coronary syndromes treated with dalteparin: a GUSTO IV substudy.
- Cancer-Associated Venous Thromboembolic Disease, Version 1.2015.
- Dalteparin thromboprophylaxis in cancer patients at high risk for venous thromboembolism: A randomized trial.
- Low molecular weight heparin (dalteparin) compared to unfractionated heparin as an adjunct to rt-PA (alteplase) for improvement of coronary artery patency in acute myocardial infarction-the ASSENT Plus study.
- Low-molecular-weight heparin to prevent postpartum venous thromboembolism. A pilot randomised placebo-controlled trial.
- Phase I/II trial of metronomic chemotherapy with daily dalteparin and cyclophosphamide, twice-weekly methotrexate, and daily prednisone as therapy for metastatic breast cancer using vascular endothelial growth factor and soluble vascular endothelial growth factor receptor levels as markers of response.
- Predictors of perioperative major bleeding in patients who interrupt warfarin for an elective surgery or procedure: Analysis of the BRIDGE trial.
- Risk factors and impact of major bleeding in critically ill patients receiving heparin thromboprophylaxis.
- Safety and efficacy of abciximab combined with dalteparin in treatment of acute coronary syndromes.
- The effects of heparins on the liver: application of mechanistic serum biomarkers in a randomized study in healthy volunteers.
- Treatment of venous thromboembolism in cancer patients with dalteparin for up to 12 months: the DALTECAN Study.